Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37001957.
- Also identified by DOI 10.1016/j.mcna.2022.12.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Biological agents have in the last two decades become very important therapeutic agents, particularly for the treatment of various autoimmune disorders. The most widely used biologics are the tumor necrosis factor-α (TNF-α) receptor antagonists: infliximab, adalimumab, and etanercept. Other commonly used biological agents are interleukin (IL)-1 receptor antagonist (Anakinra), interleukin (IL)-6 receptor antagonist (tocilizumab), and CD20 surface antigen antagonist (rituximab). The current review will however focus on TNF-α receptor antagonists.
Medical subject headings
- Antirheumatic Agents
- Biological Products
- Chemical and Drug Induced Liver Injury